Zelira Therapeutics Updates on FDA Progress

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics Ltd, a pioneer in clinically validated cannabinoid-based medicines, is set to provide an investor webinar update on its FDA progress and future plans for its HOPE product line. The company, which is actively engaged in advanced clinical trials and commercialization of products for various medical conditions, will also discuss the commercialization of its ZENIVOL product in Germany and its revenue-generating OTC products.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.